A new treatment for glaucoma that lowers eye pressure and protects nerve cells.
Novel hybrid molecule with both IOP lowering and neuroprotective effects for treatment of glaucoma
This study is testing a new treatment for glaucoma that combines two helpful properties to lower eye pressure and protect your vision, and it’s looking for patients to help see how well it works and if it’s safe.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of North Texas Hlth Sci Ctr NIH-funded |
| Lab location | 1 site (Fort Worth, United States) |
| Project ID | NIH-10927328 on NIH RePORTER |
What this research studies
This research focuses on developing a novel hybrid molecule designed to lower intraocular pressure (IOP) and provide neuroprotection for patients with glaucoma. The approach involves creating a compound that combines nitric oxide donation with superoxide dismutase mimetic properties, encapsulated in nanoparticles for enhanced delivery. By targeting both IOP reduction and the protection of retinal ganglion cells, this treatment aims to address the limitations of current therapies that often fail to prevent vision loss. Patients may be involved in trials to assess the effectiveness and safety of this new treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with glaucoma, particularly those who have not responded well to existing treatments.
Not a fit: Patients with glaucoma who are already effectively managing their condition with current therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment for glaucoma that not only lowers eye pressure but also protects against vision loss.
How similar studies have performed: Other research has shown promise in using hybrid compounds for similar therapeutic effects, but this specific approach is relatively novel.
Where this research is happening
Fort Worth, United States
- University of North Texas Hlth Sci Ctr — Fort Worth, United States (Active)
Researchers
- Principal investigator: Acharya, Suchismita — University of North Texas Hlth Sci Ctr
- Study coordinator: Acharya, Suchismita
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.